11 unknown, 8 recruiting, 7 completed, 7 terminated. 21 Phase 2, 5 Phase 1, 4 Not applicable, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Unknown 7, Completed 5, Not yet recruiting 4, Recruiting 3, Terminated 2 |
| Phase 1 | 5 | Terminated 5 |
| Not applicable | 4 | Recruiting 3, Unknown 1 |
| Phase 3 | 2 | Recruiting 2 |
| Phase 4 | 1 | Terminated 1 |
Follow EGFR Activating Mutation: new trials by email Literature Review of EGFR Activating Mutation trials Research Report on EGFR Activating Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection - NSCLC, EGFR Activating Mutation | Phase 2 | Not yet recruiting | Zhou Chengzhi | 100 | 2026-07-01 | 2026-07-06 |
| EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC EGFR-TKIs Combined with PD-1 Monoclonal Antibody - Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 32 | 2026-05-21 | 2026-06-09 |
| Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis Furmonertinib 320mg qod po, Furmonertinib 160mg qd po - NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis | Not applicable | Recruiting | Guangzhou University of Traditional Chinese Medicine | 42 | 2026-03-01 | 2026-04-02 |
| Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data Comprehensive analysis through laboratory tests, imaging techniques, and clinical data - Lung Cancer (NSCLC), EGFR Activating Mutation | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1000 | 2025-12-25 | 2025-12-17 | |
| High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC Firmonertinib Mesilate Tablets, Bevacizumab injection - NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 62 | 2025-10-01 | 2025-09-19 |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer BG-60366 - Non-Small Cell Lung Cancer, Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 33 | 2024-12-05 | 2026-05-22 |
| Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial Osimertinib plus Dalpiciclib - Non-small Cell Lung Cancer, EGFR Activating Mutation | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 32 | 2024-04-09 | 2024-04-16 |
| A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) Plasma ctDNA, FFPE blocks - Non Small Cell Lung Cancer, EGFR Activating Mutation | Not applicable | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 300 | 2024-01-22 | 2024-03-08 |
| TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases TY-9591, Osimertinib - NSCLC, EGFR Activating Mutation | Phase 2 | Recruiting | TYK Medicines, Inc | 420 | 2023-08-17 | 2026-08-25 |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation Aumolertinib,Anlotinib - Aumolertinib, Anlotinib | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 47 | 2023-03-31 | 2023-03-21 |
| Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases brain radiotherapy, Almonertinib - Brain Metastases, Radiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 232 | 2023-03-15 | 2023-03-14 |
| CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease Lumbar puncture and Phlebotomy - EGFR Activating Mutation, Leptomeningeal Metastasis | Not applicable | Recruiting | British Columbia Cancer Agency | 10 | 2022-07-18 | 2026-10-19 |
| Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations Pembrolizumab, Lenvatinib, Carboplatin - Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation | Phase 2 | Completed | Juntendo University | 30 | 2022-07-01 | 2026-07-29 |
| Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) TY-9591, placebo Osimertinib, Osimertinib - NSCLC, EGFR Activating Mutation | Phase 3 | Recruiting | TYK Medicines, Inc | 680 | 2022-06-08 | 2024-01-30 |
| Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC Sintilimab, Carboplatin, Nab paclitaxel - Non-small Cell Lung Cancer, EGFR Activating Mutation | Phase 2 | Unknown | Guangdong Provincial People's Hospital | 35 | 2022-06-04 | 2024-07-08 |
| Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation TY-9591 Tablets - NSCLC, EGFR Activating Mutation | Phase 2 | Completed | TYK Medicines, Inc | 29 | 2022-04-02 | 2024-12-30 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model Collection of surgical waste - Lung Cancer, Lung Adenocarcinoma | Unknown | Central Hospital, Nancy, France | 200 | 2021-11-01 | 2021-11-26 |
Showing 20 of 39. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (27) · Lung Neoplasms (9) · Meningeal Carcinomatosis (7) · Adenocarcinoma of Lung (5) · Brain Neoplasms (5) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3)
Neoplasms (31) · Neoplasms by Site (31) · Respiratory Tract Neoplasms (27) · Thoracic Neoplasms (27) · Bronchial Neoplasms (24) · Carcinoma, Bronchogenic (24) · Lung Diseases (24) · Respiratory Tract Diseases (24) · Lung Neoplasms (21) · Central Nervous System Neoplasms (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neoplasms, Glandular and Epithelial (8) · Meningeal Neoplasms (6) · Adenocarcinoma (5)
osimertinib (9) · Carboplatin (8) · Pemetrexed (7) · Bevacizumab (5) · aumolertinib (5) · pembrolizumab (3) · Cisplatin (2) · Drug Therapy (2) · Gemcitabine (2) · Nivolumab (2) · lenvatinib (2) · Adjuvants, Immunologic (1) · Diagnostic Imaging (1) · Gefitinib (1) · High-Throughput Nucleotide Sequencing (1)
Blueprint Medicines Corporation (3) · Second Affiliated Hospital of Nanchang University (3) · TYK Medicines, Inc (3) · Intergroupe Francophone de Cancerologie Thoracique (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · BeOne Medicines (1) · British Columbia Cancer Agency (1) · Central Hospital, Nancy, France (1) · Dr Joanne CHIU (1) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · First People's Hospital of Hangzhou (1) · Fudan University (1) · Guangdong Provincial People's Hospital (1) · Guangzhou University of Traditional Chinese Medicine (1)
China (20) · United States (6) · France (4) · South Korea (4) · Canada (3) · Japan (3) · Hong Kong (2) · Spain (2) · Taiwan (2) · Australia (1) · Italy (1) · Netherlands (1) · New Zealand (1) · Singapore (1) · United Kingdom (1)
Liu Anwen, Phd (2) · Yuankai Shi, MD (2) · Baohui Han, MD (1) · Cheryl Ho, MD (1) · Haibo Zhang, M.D. (1) · In Ae Kim, MD. Ph.D (1) · Junling Li, MD (1) · Likun Chen (1) · Lin Wu, MD (1) · Liu Anwen, PhD (1) · Rafael Santana-Davila (1) · Ryo Ko, MD, PhD (1)
PMID 30059262, PMID 15118073, PMID 15118125, PMID 15886314, PMID 16642476, PMID 17374728, PMID 17894407, PMID 19470276, PMID 20087963, PMID 20573926, PMID 22487432, PMID 24002608, PMID 24893891, PMID 25175099, PMID 26334749, PMID 27539328, PMID 28105214, PMID 28627678, PMID 29151359, PMID 29190637, PMID 29307353, PMID 29700687, PMID 29782558, PMID 30039345, PMID 30975627, PMID 31085043, PMID 31108248, PMID 31591063, PMID 31751012, PMID 31809241, PMID 31865717, PMID 32352148, PMID 33205587, PMID 33334576, PMID 33962566, PMID 36773776, PMID 39398493, PMID 39954935, PMID 41212380, PMID 42256683
P30CA012197 (1), P30CA015704 (1)